Terns Pharmaceuticals, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Quigley Jill M. | — | Option Exercise | 24,520 | $9.24 | $226,565 | 24,520 | Nov 4, 2025 |
| Kuriakose Emil | Chief Medical Officer | Sale | 944 | $7.85 | $7,410 | 51,520 | Oct 1, 2025 |
| Kuriakose Emil | Chief Medical Officer | Sale | 853 | $4.27 | $3,642 | 52,464 | Jul 1, 2025 |
| Gengos Andrew | Chief Financial Officer | Purchase | 5,000 | $3.93 | $19,650 | 20,000 | Jun 27, 2025 |
| Burroughs Amy L. | Chief Executive Officer | Purchase | 23,314 | $3.87 | $90,225 | 47,083 | Jun 25, 2025 |
| Gengos Andrew | Chief Financial Officer | Purchase | 5,000 | $3.72 | $18,600 | 10,000 | Jun 16, 2025 |
| Kuriakose Emil | Chief Medical Officer | Sale | 952 | $2.49 | $2,370 | 53,317 | Apr 1, 2025 |
| Vignola Mark J. | Chief Financial Officer | Sale | 8,129 | $5.72 | $46,498 | 83,811 | Jan 6, 2025 |
| Quigley Jill M. | — | Sale | 6,240 | $5.72 | $35,693 | 8,760 | Jan 6, 2025 |
| Kuriakose Emil | Chief Medical Officer | Sale | 4,481 | $5.71 | $25,587 | 54,269 | Jan 2, 2025 |
| Burroughs Amy L. | Chief Executive Officer | Purchase | 15,450 | $7.15 | $110,468 | 19,099 | Dec 5, 2024 |
| Jung Melita Sun | Chief Business Officer | Purchase | 2,250 | $5.11 | $11,498 | 2,250 | Nov 30, 2024 |
| Burroughs Amy L. | Chief Executive Officer | Purchase | 510 | $5.11 | $2,606 | 19,609 | Nov 30, 2024 |
| Lu Hongbo | — | Purchase | 190,476 | $10.50 | $1,999,998 | 190,476 | Sep 12, 2024 |
| Vignola Mark J. | Chief Financial Officer | Sale | 10,000 | $11.00 | $110,000 | 91,940 | Sep 10, 2024 |
| Quigley Jill M. | — | Option Exercise | 17,235 | $1.82 | $31,368 | 32,235 | Sep 9, 2024 |
| Quigley Jill M. | — | Sale | 8,857 | $7.50 | $66,428 | 15,000 | Aug 1, 2024 |
| OrbiMed Genesis GP LLC | — | Sale | 556 | $10.00 | $5,560 | 1,967,924 | Jul 16, 2024 |
| GORDON CARL L | — | Sale | 556 | $10.00 | $5,560 | 1,967,924 | Jul 15, 2024 |
| Quigley Jill M. | — | Sale | 400 | $10.00 | $4,000 | 30,000 | Jul 15, 2024 |
| Yoon Seokho Bryan | COO and General Counsel | Purchase | 4,791 | $4.44 | $21,272 | 91,940 | May 31, 2024 |
| Vignola Mark J. | Chief Financial Officer | Purchase | 4,791 | $4.44 | $21,272 | 91,940 | May 31, 2024 |
| Vivo Opportunity, LLC | — | Sale | 4,149 | $6.20 | $25,724 | 268,573 | Apr 2, 2024 |
| Quigley Jill M. | Sr. Advisor & Strategy Officer | Award / Grant | 15,000 | — | — | 30,000 | Jan 23, 2024 |
| Yoon Seokho Bryan | COO and General Counsel | Award / Grant | 68,750 | — | — | 87,149 | Jan 23, 2024 |
| Vignola Mark J. | Chief Financial Officer | Award / Grant | 68,750 | — | — | 87,149 | Jan 23, 2024 |
| Quirk Erin | President, Head of R&D | Award / Grant | 75,000 | — | — | 75,000 | Jan 23, 2024 |
| Yoon Seokho Bryan | COO and General Counsel | Purchase | 743 | $3.78 | $2,809 | 18,399 | Nov 30, 2023 |
| Vignola Mark J. | Chief Financial Officer | Purchase | 743 | $3.78 | $2,809 | 18,399 | Nov 30, 2023 |
| Quigley Jill M. | Sr. Advisor & Strategy Officer | Award / Grant | 15,000 | — | — | 15,000 | Nov 15, 2023 |
| Vignola Mark J. | Chief Financial Officer | Purchase | 9,997 | $1.41 | $14,096 | 17,656 | May 31, 2023 |
| Yoon Seokho Bryan | COO and General Counsel | Purchase | 9,997 | $1.41 | $14,096 | 17,656 | May 31, 2023 |
| Sundaram Senthil Vel | Chief Executive Officer | Purchase | 2,111 | $1.41 | $2,977 | 9,770 | May 31, 2023 |
| Lu Hongbo | — | Purchase | 758,620 | $7.25 | $5,499,995 | 4,340,212 | Dec 23, 2022 |
| Vivo Opportunity Fund Holdings, L.P. | — | Purchase | 758,620 | $7.25 | $5,499,995 | 4,340,212 | Dec 23, 2022 |
| GORDON CARL L | — | Purchase | 137,931 | $7.25 | $1,000,000 | 4,882,854 | Dec 23, 2022 |
| OrbiMed Genesis GP LLC | — | Purchase | 137,931 | $7.25 | $1,000,000 | 4,882,854 | Dec 23, 2022 |
| Yoon Seokho Bryan | COO and General Counsel | Purchase | 3 | $1.41 | $4 | 7,659 | Nov 30, 2022 |
| Vignola Mark J. | Chief Financial Officer | Purchase | 3 | $1.41 | $4 | 7,659 | Nov 30, 2022 |
| Sundaram Senthil Vel | Chief Executive Officer | Purchase | 3 | $1.41 | $4 | 7,659 | Nov 30, 2022 |
| Oriental Spring Venture Ltd | — | Sale | 166,666 | $5.50 | $916,663 | 529,762 | Nov 23, 2022 |
| Lu Hongbo | — | Purchase | 600,000 | $3.60 | $2,160,000 | 3,581,592 | Sep 7, 2022 |
| Vivo Opportunity, LLC | — | Purchase | 600,000 | $3.60 | $2,160,000 | 3,581,592 | Sep 7, 2022 |
| GORDON CARL L | — | Purchase | 457,400 | $2.42 | $1,106,908 | 1,973,881 | Aug 16, 2022 |
| OrbiMed Capital GP VII LLC | — | Purchase | 457,400 | $2.42 | $1,106,908 | 1,973,881 | Aug 16, 2022 |
| Vivo Capital Surplus Fund VIII, L.P. | — | Purchase | 1,500,000 | $2.42 | $3,630,000 | 2,981,592 | Aug 15, 2022 |
| Lu Hongbo | — | Purchase | 1,218 | $2.99 | $3,642 | 1,481,592 | Aug 12, 2022 |
| Sundaram Senthil Vel | Chief Executive Officer | Purchase | 7,656 | $1.47 | $11,254 | 7,656 | May 31, 2022 |
| Vignola Mark J. | Chief Financial Officer | Purchase | 7,656 | $1.47 | $11,254 | 7,656 | May 31, 2022 |
| Yoon Seokho Bryan | COO and General Counsel | Purchase | 7,656 | $1.47 | $11,254 | 7,656 | May 31, 2022 |